Click to go to DrugInjuryLaw Home


Legal information and news about prescription drug side effects
NuvaRing Case Evaluation Ortho Evra Case Evaluation Fosamax Case Evaluation Avandia Case EvaluationKetek Case Evaluation Zelnorm Case Evaluation Meridia Case Evaluation Zocor Case Evaluation
Vytorin Case EvaluationZetia Case Evaluation Yasmin Case Evaluation Ocella Case EvaluationYAZ Case Evaluation Levaquin Case Evaluation Byetta Case Evaluation Gianvi Case Evaluation


Free Case Evaluation

Judge Sippel Schedules A December 1, 2009 "Science Day" For NuvaRing MDL Litigation

Each Side Will Present Their Information About Issue Of Whether Or Not The NuvaRing Is An Unsafe Birth Control Device

UPDATE:  During this one-day “Science Day” on December 1, 2009 the plaintiffs called upon a hematologist who explained how blood clots can develop in women using the NuvaRing, and the drug company relied upon a leading gynecologist to assert that the NuvaRing is safe and wonderful.

There was no indication from Judge Sippel what he thought about these "competing" presentations.

As expected, all information presented at this Science Day was deemed confidential, was not done under oath, and did not address any specific Plaintiff's case.


U.S. District Judge Rodney W. Sippel, who is presiding over In Re NuvaRing Products Liability Litigation (MDL 1964) -- the NuvaRing federal court MDL -- has scheduled a one-day “Science Day” for December 1, 2009.

On that day Judge Sippel will listen to presentations on (1) the Plaintiffs’ theory about how the NuvaRing causes an increased risk of serious blood clots, and (2) drug company’s contention that the NuvaRing is not a dangerous nor unsafe birth control method.

The purpose of these Science Day presentations is to educate Judge Sippel about the NuvaRing's combination of ethinyl estradiol and etonogestrel (a so-called "third generation" progestin) and the issue of whether, due to that chemical combination, the NuvaRing increases one's risk of developing serious side effects such as deep vein thrombosis (DVT) and pulmonary embolism (PE).

Plaintiffs have alleged that the drug company failed to fully research the safety of the NuvaRing before putting it on the market and, in turn, failed to adequately warn women together with their doctors about the increased risk of developing blood clots.

Reportedly, all information presented at this NuvaRing MDL Science Day will be deemed confidential, will not be done under oath, and will not address any specific Plaintiff's case.

Go to Free NuvaRing Case Evaluation form >>

Read more on the NuvaRing Information Page >>


  • US FDA advises that you should not stop taking any prescription medication before talking to your doctor.
  • Reports of serious drug side effects should be made to the US FDA MedWatch program.
  • The prescription drug names are registered trademarks of the respective drug companies.
  • DrugInjuryLaw.com is not affiliated with any of the drug companies, nor US FDA.
Law Offices of Thomas J. Lamb, P.A.
Lumina Station Suite 225
1908 Eastwood Road
Wilmington, NC 28403
Tel: (910) 256-2971   Fax: (910) 256-2972
Toll Free: (800) 426-9535
email: ThomasJLamb@DrugInjuryLaw.com

Disclaimer